Skip to main contentSkip to navigation
Sirius Investors

BIOA-B.ST Stock: BioArctic AB (publ) Stock Price, Analysis & Insights

Get live BIOA-B.ST stock price $302.40, comprehensive BioArctic AB (publ) stock analysis, charts, news, and expert forecast. Real-time BIOA-B.ST stock data and investment insights.

302.40
4.71%Today
BIOA-B.STBioArctic AB (publ) • Stockholm Stock Exchange • Healthcare
Market Cap
26.79B
Volume
157.78K
52W High
364.40
52W Low
174.50

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

BioArctic AB (publ) is a Swedish biopharmaceutical firm heavily engaged in research, dedicated to creating biological therapies for individuals afflicted by neurodegenerative conditions. A primary candidate in their pipeline is BAN2401, an immunother...

Company Information

CEO
Gunilla Osswald
Sector
Healthcare
Industry
Biotechnology
Employees
107

Contact Information

Address
Warfvinges vag 35
Country
SE

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Growth-oriented company with premium valuation (P/E: 127.6)

Lower volatility stock (Beta: -0.76) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for BioArctic AB (publ) shareholders
  • Market volatility can significantly impact stock price, especially for mid-cap stocks
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for BioArctic AB (publ)
  • Investors should consider how BioArctic AB (publ) fits within their overall portfolio allocation
  • Premium valuation (P/E: 127.6) requires strong growth to justify

Market Cap

26.79B

P/E Ratio (TTM)

127.59

Beta

-0.76

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

43/100 ⭐⭐⭐

Overall
-1.0%
NYSE
-1.6%
NASDAQ
-0.4%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.3%+1.9%19.8
83/100⭐⭐⭐⭐⭐
Technology+0.8%+1.1%+3.0%52.0
76/100⭐⭐⭐⭐⭐
Basic Materials+0.8%+0.3%+1.9%27.9
69/100⭐⭐⭐⭐
Industrials-0.3%-0.9%+2.7%43.0
64/100⭐⭐⭐⭐
Communication Services-0.8%-1.3%+0.4%21.9
48/100⭐⭐⭐
Consumer Defensive+0.6%+1.6%-2.5%31.2
44/100⭐⭐⭐
Healthcare-1.0%-2.0%+1.5%30.5
43/100⭐⭐⭐
Real Estate+0.5%-1.1%-0.0%50.0
33/100⭐⭐
Energy+0.5%-3.6%-0.0%35.9
31/100⭐⭐
Utilities+2.0%-1.3%-5.1%26.1
31/100⭐⭐
Consumer Cyclical-0.3%+0.3%-0.2%55.8
28/100⭐⭐

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.